Y
Yu Shyr
Researcher at Vanderbilt University Medical Center
Publications - 582
Citations - 45668
Yu Shyr is an academic researcher from Vanderbilt University Medical Center. The author has contributed to research in topics: Cancer & Lung cancer. The author has an hindex of 98, co-authored 542 publications receiving 39527 citations. Previous affiliations of Yu Shyr include Vanderbilt University & Ninewells Hospital.
Papers
More filters
Journal ArticleDOI
Molecular classification of triple negative breast cancer
Journal ArticleDOI
Kidney Stone History and Adverse Outcomes After Percutaneous Coronary Intervention.
Chao Han Lai,Li-Ching Huang,S. Neil Holby,Ying Ju Lai,Pei Fang Su,Yu Sheng Cheng,Yu Shyr,Ryan S. Hsi +7 more
TL;DR: Kidney stone history is associated with poorer cardiac outcomes after percutaneous coronary intervention and improving secondary cardiac prevention strategies after PCI may be necessary for patients with a history of kidney stone disease.
BASIC—ALIMENTARY TRACT Experimentally Derived Metastasis Gene Expression Profile Predicts Recurrence and Death in Patients With Colon Cancer
Joshua J. Smith,Natasha G. Deane,Fei Wu,Nipun B. Merchant,Bing Zhang,Aixiang Jiang,Pengcheng Lu,J. Chad Johnson,Carl Schmidt,Christina E. Bailey,Steven Eschrich,Christian Kis,Shawn Levy,M. Kay Washington,Martin J. Heslin,Robert J. Coffey,Timothy J. Yeatman,Yu Shyr,R. Daniel Beauchamp,Hyunhwan Lee +19 more
TL;DR: A gene expression profile identified from an experimental model of colon cancer metastasis predicted cancer recurrence and death, independently of conventional measures, in patients with colon cancer.
Journal ArticleDOI
Urine PGE-M to assess prostaglandin E2 (PGE2) levels in non-small cell lung cancer (NSCLC)
Leora Horn,Ginger L. Milne,Alan B. Sandler,Jason D. Morrow,David P. Carbone,Yu Shyr,A. Hayes,N. Campbell,David H. Johnson +8 more
TL;DR: Preliminary data indicate C 600 mg bid effectively inhibits intratumoral COX-2 in >50% NSCLC pts, a higher percentage than the previous trial using C 400 mg bid.
Journal ArticleDOI
Urine PGE-M as a marker of intratumoral cyclooxygenase-2 activity in non-small cell lung cancer (NSCLC)
Ildiko Csiki,M. K. Williams,Yu Shyr,Alan Sandler,D. P. Carbone,N. Campbell,Jason D. Morrow,David H. Johnson +7 more
TL;DR: This data indicates that prostaglandin E2 levels are elevated in NSCLC often in association with overexpression of cyclooxygenase-2 (COX2) and this data points to the need to characterize PGE2 levels further to establish a causative mechanism.